ㅣ의 조음 특성에 관한 연구

조오현 ( Oh Hyun Cho ) 한말연구학회 2001 한말연구 Vol.- No.9

This study is experimental and in this study, the hypothesis written by Cho Oh-hyun (1998, 1999), which suggests the difference between the phonetic value of `ㅣ` in 15th century and at the present time, will be tested and examined. The method taken for experiment is that a sound value is assumed by analysing sounds, and the theoretical background and the method and the consequency of the experiment are described below: 1) The theoretical background ① Referring to the nature [+high] of `ㅣ` containing a wide variety of phonemic phenomenon and the explanation in 「Hun Min Jeong Yem - the Korean script」, the sound of `ㅣ` was possibly articulated in the area of the neutral position in the 15th century, however, at present it has been changed in to a unvoiced vowel and become the presently used [+high] sound of `ㅣ`. ② ① A wide variety of phonemic phenomenon, which did not exist in the 15th century, has been generated, for example, `ㄷ` palatalization and `ㄴ` a law of the initial sound of a syllable, a dental sound of `ㅈ`, `ㅊ`, `ㅉ` being changed to a palatal sound, a inherited overlapping vowel being changed to a single vowel and round vowelization. 2) a method for the experiment Seven male students from Seoul and seven male students from Kyeng-Ki provice, who are in the third year at Kon-kuk university, were selected and trained to be able to pronounce `ㅈ`, `ㅊ`, `ㅉ` both with a palatal sound and with a gum sound, and then `ㅣ` sound was abstracted and analyzed by the method suggested by P. Ladefoged in order to decide a range. The range already decided mentioned above were used to compare between the ranges of the presently used `ㅣ` and surrounding sounds of `ㅡ`, `ㅓ`, `ㅔ`. 3) the result of the experiment The experiment has proven that the phonetic value of `ㅣ` being articulated a sound which was higher than `ㅓ` position and in front of `ㅓ` position in the 15th century, is different from the sound of `ㅣ` presently used. As a result of the experiment, it is concluded that the sound of `ㅣ` was pronounced from near neutral position and the sound easily pronounced, which is explained in `Jung Seoung Hae in 「Hun Min Jeong Yem - the Korean script」is the same meaning of the neutral position.

치과용 심미 수복 재료들의 색상 연구를 통한 새로운 치과용 색체계의 제안

오윤정,박수정,김동준,조현구,황윤찬,오원만,황인남 대한치과보존학회 2007 Restorative Dentistry & Endodontics Vol.32 No.1

본 연구는 새로운 치과용 색체계 개발을 목적으로 현재 치과에서 사용되고 있는 Vita shade를 사용하는 9 제조사의 12종의 광중합형 복합레진과 1종의 치과용 도재의 색상을 diffuse/8° 수광 방식을 사용하는 분광색체계 (MiniScan XE plus, Model 4000S, Hunter Lab, USA)를 이용해 D65 표준광과 10도 관찰자 시야 하에서 CIE L^(*)a^(*)b^(*) 값을 측정하고 색상 범위를 분석하였다. 분석한 정보를 color sorting system을 응용한 CNU Cons Dental Color Chart의 색상 표현 방식인 T###에 치과용 수복 재료들의 범위를 적용하여 다음의 결과를 얻었다. 측정된 L^(*)a^(*)b^(*)값의 분포를 분석해 보면 L^(*)값은 80.40과 52.70 사이에, a^(*)값은 10.60과-3.60 사이에, 그리고 b^(*)값은 28.40과 2.21 사이에 분포한다. L^(*)값의 평균값은 67.40, 중앙값은 67.30이며, a^(*)값은 2.89와 2.91, b^(*)값은 14.30 과 13.90 이다. 이러한 분석을 토대로 CNU Cons Dental Color Chart의 T###의 첫 번째 숫자에 해당하는 L^(*)값의 각 숫자간의 차이는 2.0으로, 그리고 2번째 숫자인 a^(*)값의 각 숫자간의 차이는 1, 그리고 세 번째 숫자인 b^(*)값의 각 숫자간의 차이는 2로 정하였다. T555에 해당하는 L^(*)값의 범위는 66.0이상, 68.0미만으로, a^(*)값의 범위는 3이상 4미만으로, b^(*)값의 범위는 14이상 16미만으로 결정하였다. The purpose of this study is to develope new dental color-space system. Twelve kinds of dental composites and one kind of dental porcelain were used in this study. Disk samples (15 ㎜ in diameter, 4 ㎜ in thickness) of used materials were made and sample’s CIE L^(*)a^(*)b^(*) value was measured by Spectrocolorimeter (MiniScan XE plus, Model 4000S, diffuse/8° viewing mode, 14.3 ㎜ Port diameters, Hunter Lab. USA). The range of measured color distribution was analyzed. All the data were applied in the form of T### which is expression unit in CNU Cons Dental Color Chart. The value of L^(*) lies between 80.40 and 52.70. The value of a^(*) are between 10.60 and 3.60 and b^(*) are between 28.40 and 2.21. The average value of L^(*) is 67.40, and median value is 67.30. The value of a^(*) are 2.89 and 2.91 respectively. And for the b^(*), 14.30 and 13.90 were obtained. The data were converted to T### that is the unit count system in CNU-Cons Dental Color Chart. The value of L^(*) is converted in the first digit of the numbering system. Each unit is 2.0 measured values. The second digit is the value of a^(*) and is converted new number by 1.0 measured value. For the third digit b^(*) is replaced and it is 2.0 measured unit apart. T555 was set to the value of L^(*) ranging from 66.0 to 68.0, value of a^(*) ranging from 3 to 4 and b^(*) value ranging from 14 to 16.

복합레진의 표면거칠기에 따른 투명도와 표면 색상의 차이에 관한 연구

조규정,박수정,조현구,김동준,황윤찬,오원만,황인남 大韓齒科保存學會 2006 Restorative Dentistry & Endodontics Vol.31 No.4

본 연구는 복합레진의 표면 연마에 의한 표면 거칠기가 표면 색상과 투명도에 어떤 영향을 미치는가를 알아보고자 시행하였다. Charisma (Heraeus Kulzer GmbH, Domagen, Germany)의 B1과 A3, Esthet-X (DENTSPLY Caulk, Milford, USA)의 B1과 B3 레진으로 거칠기에 따른 표면 색상을 평가하기 위한 직경 8㎜, 두께 5㎜의 시편을 제작하고, Sof-Lex finishing & polishing system(3M, ESPE Dental Products. St. Paul USA)의 C, M, F, 및 SF 디스크로 시편의 한쪽 면을 연마하였으며, 연마 전 Mylar strip으로 압축된 면을 대조군으로 하였다. 거칠기에 따른 투명도의 차이를 평가하기 위한 두께 1 ㎜의 시편을 Charisma의 A3로 제작하여, 한쪽 면을 600, 1000, 1500 및 2000번 사포로 연마하였다. 각 시편의 연마 전과 후, 연마면의 CIE L^(*)a^(*)b^(*)값과 1 ㎜ 시편의 백색과 흑색 배경판 상에서의 Y값을 spectrophotometer인 Spectrolino (GretagMacbech, Regensdorf, Switzerland)를 사용해 측정 분석하였으며, 각 시편의 연마 전과 후의 평균 표면 조드 (Ra)값을 Surface Roughness Tester SJ-301 (Mytutoyo, Tokyo, Japan)로 측정했다. L^(*)값은 재료와 색상에 상관없이 가장 거친 Sof-lex C 디스크로 연마한 군에서 가장 높은 값을 보였으며 (p < 0.05). Esthet-X B3군을 제외한 모든 군에서 Ra값이 감소함에 따라 L^(*)값도 낮아졌다. a^(*)값은 표면 거칠기에 따라 특정한 변화 양상을 보이지 않았으며, b^(*)값은 Esthet-X B1군을 제외한 모든 군에서 Sof-lex SF 디스크로 연마 시 가장 높은 값을 보였으며 (p < 0.05), Charisma B1과 Esthet-X B3군에서 Ra값과 비교적 높은 상관 관계를 보였다. Contrast ratio는 1000번과 1500번 사포로 연마한 군간을 제외한 모든 군 간에 유의한 차이를 보여으며 (p < 0.05). 표면 거칠기가 감소함에 따라 contrast ratio도 감소하였다(R2 = 0.801). The objectives of this were to evaluate the effect of surface roughness on the surface color and translucency of the composite reins. Two composite resins (Esthet-X, Dentsply, Milford, USA and Charisma, Kulzer, Domagen, Germany) were used to investigate the surface color. Charisma was used to investigate the translucency. 40 disc samples (diameter: 8 ㎜, thickness: 5 ㎜) were made by each product to measure the surface color. Ploymerized each sample's one side was treated by Sof-Lex finishing and polishing system (Group C, M, F, SF). 40 disc samples (diameter: 6 ㎜, thickness: 1 ㎜) were prepared to measure the opacity. 1 ㎜ samples were ground one side with #600, #1000, #1500 and #2000 sandpapers. CIE L^(*)a^(*)b^(*) values of each 5 ㎜ thickness samples, and XYZ values of 1 ㎜ thickness samples on the white and black background were measured with spectrophotometer (Spectrolino, GretagMacbeth, Regensdorf, Switzerland). Mean surface roughness (Ra) of all samples before and after surface treatment was measured using the Surface Roughness Tester SJ-301 (Mytutoyo, Tokyo, Japan). Regardless of type and shade of the composite resin, L^(*) values measured in group C were higher than others (p < 0.05), and L^(*) value decreased as the Ra value decreased except B3 shade of Esthet-X. But there were no significant difference in a^(*) values among groups. In control group and SF, highest b^(*) values were measured (p < 0.05), except B1 shade of Esthet-X. Contrast ratio decreased as the Ra value decreased (p < 0.05). With the above results, difference of surface roughness has influence on surface color and translucency of dental composite resins. 〔J Kor Acad Cons Dent 31(4):312-322, 2006〕

무코스타정(레바미피드 100mg)에 대한 레바미드 정의 생물학적 동등성

조혜영,정현철,오인준,문재동,이용복 한국약제학회 2001 Journal of Pharmaceutical Investigation Vol.31 No.4

Rebamipide is a novel anti-gastric ulcer agent that has been reported to increase the synthesis of mucus, to increase the mucosal concentration of prostaglandin, and to promote rapid ulcer healing. The purpose of the present study was to evaluate the bioequivalence of two rebamipide tablets, Mucosta^TM (Otsuka Korea Pharmaceutical Co., Ltd.) and Rebamide^TM (Kyung Dong Pharmaceutical Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). The rebamipide release from the two rebamipide tablets in vitro was tested using KP VII Apparatus II method at pH 6.8 dissolution media. Twenty normal male volunteers, 24.20±2.26 years in age and 66.19±9.41 kg in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After one tablet containing 100 mg of rebamipide was orally administered, blood was taken at predetermined time intervals and the concentrations of rebamipide in serum were determined using HPLC method with fluorescence detector. The dissolution profiles of two rebamipide tablets were very similar at pH 6.8 dissolution media. Besides, the pharmacokinetic parameters such as AUC_t C_max and T_max were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in AUC_t C_max and T_max between two tablets based on the Mucosta^TM were -2.57%, 5.77% and -1.47%, respectively. Minimum detectable differences (Δ) at α=0.05 and 1-β=0.8 were less than 20% (e.g., 12.62% and 17.63% for AUC_t and C_max respectively). The powers (1-β) at α=0.05, Δ=0.2 for AUC_t and C_max were above 99.00% and 88.56%, respectively. The 90% confidence intervals were within 20% (e.g., -9.96∼4.82 and -4.54∼16.09 for AUC_t and C_max respectively). Two parameters met the criteria of KFDA for bioequivalence, indicating that Rebamide^TM tablet is bioequivalent to Mucosta^TM tablet.

무코스타 정(레바미피드 100 mg) 에 대한 레바미드 정의 생물학적 동등성

조혜영,정현철,오인준,문재동,이용복 전남대학교 약품개발연구소 2001 약품개발연구지 Vol.10 No.-

Rebamipide is a novel anti-gastric ulcer agent that has been reported to increase the synthesis of mucus. to increase the mucosal concentration of prostaglandin, and to promote rapid ulcer healing. The purpose of the present study was to evaluate the bioequivalence of two rebamipide tablets, Mucosta^TM (Otsuka Korea Pharmaceutical Co., Ltd.) and Rebamide^TM (Kyung Dong Pharmaceutical Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). The rebamipide release from the two rebamipide tablets in vitro was tested using KP Ⅶ Apparatus Ⅱ method at pH 6.8 dissolution media. Twenty normal male volunteers, 24.20±2.26 years in age and 66.19±9.41㎏ in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After one tablet containing 100㎎ of rebamipide was orally administered, blood was taken at predetermined time intervals and the concentrations of rebamipide in serum were determined using HPLC method with fluorescence detector. The dissolution profiles of two rebamipide tablets were very similar at pH 6.8 dissolution media. Besides, the pharmacokinetic parameters such as AUC_t, C_max and T_max were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in AUC_t, C_max and T_max between two tablets based on the Mucosta^TM were -2.57%, 5.77% and - 1.47%, respectively. Minimum detectable differences (Δ) at α=0.05 and 1-β=0.8 were less than 20% (e.g., 12.62% and 17.63% for AUC_t and C_max, respectively). The powers (1-β) at α=0.05, Δ=0.2 for AUC_t and C_max. were above 99.00% and 88.56%, respectively. The 90% confidence intervals were within ±20% (e.g., -9.96~4.82 and -4.54~16.09 for AUC_t and C_max respectively). Two parameters met the criteria of KFDA for bioequivalence, indicating that Rebamide^TM tablet is bioequivalent to Mucosta^TM tablet.

니세틸 정(아세틸-엘-카르니틴 500 mg)에 대한 뉴로세틸 정의 생물학적 동등성

조혜영,김은아,정현철,심영순,임동구,오인준,문재동,이용복 전남대학교 약품개발연구소 2001 약품개발연구지 Vol.10 No.-

Acetyl-L-carnitine (ALC), an endogenous component of the L-carnitine family, is naturally occurring molecule synthesized from L-carnitine (LC) by carnitine acetyl transferase. ALC has been shown to improve the cognitive performance of patients suffering from dementia of the Alzheimer's type and proposed for treating Alzheimer's disease in pharmacological doses. The purpose of the present study was to evaluate the bioequivalence of two ALC tablets, Nicetiler^TM (Dong-A pharmaceutical Co., Ltd.) and Neurocetil^TM (Kyung-Dong Pharmaceutical Co., Ltd.), according to the guidelines of Korea Food and Drug Administration. Twenty six normal male volunteers, 22.80±2.76 year in age and 63.07 7.98㎏ in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After one tablet containing 500㎎ of ALC was orally administered, blood was taken at predetermined time intervals and the concentrations of ALC in serum were determined using HPLC with fluorescence detector. Because of the presence of endogenous ALC, the calibration was performed using dialyzed serum. Pharmacokinetic parameters such as AUC_t, C_max and T_max were calculated and ANOVA was utilized for the statistical analysis of the parameters. The results showed that the differences in AUC_t, C_max and T_max between two tablets were 2.72%, -0.65% and -8.42%, respectively, when calculated against the Nicetile^TM tablet. The powers (1-β) for AUC_t and C_max were 94.87% and 87.17%, respectively. Minimum detectable differences (Δ) at α=0.05 and 1-β=0.8 were less than 20% (e.g., 15.58% and 19.16% AUC_t and C_max, respectively). The 90% confidence intervals were within ±20% (e.g., -11.84∼6.41 and -10.57∼11.88 for AUC_t and C_max, respectively). Two parameters met the criteria of KFDA for bioequivalence, indicating that Neurocetil^TM tablet is bioequivalent to Nicetile^TM tablet.

비유피-4 정(염산프로피베린 20㎎)에 대한 건일염산프로피베린 정의 생물학적동등성

조혜영,박은자,강현아,백승희,김세미,박찬호,오인준,문재동,이용복 한국약제학회 2004 Journal of Pharmaceutical Investigation Vol.34 No.5

The purpose of the present study was to evaluate the bioequivalence of two propiverine hydrochloride tablets. BUP-4 (Jeil Pharm. Co., Ltd.) and Kuhnil Propiverine Hydrochloride (Kuhnil Pharm. Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The propiverine release from the two propiverine hydrochloride formulations in vitro was tested using KP Ⅷ Apparatus Ⅱ method with a variety of dissolution media (pH 1.2, 4.0, 6.8 buffer solutions, water and blend of polysorbate 80 into pH 6.8). Twenty six healthy male subjects, 23.73 ± 2.79 years in age and 67.04 ± 7.93 kg in body weight, were divided into two groups and a randomized 2 x 2 cross-over study was employed. After one tablet containing 20 mg as propiverine hydrochloride was orally administered, blood was taken at predetermined time intervals and the concentrations of propiverine in serum were determined using HPLC method with UV detector. The dis-solution profiles of two formulations were similar at all dissolution media. Besides, the pharmacokinetic parameters such as AUC" C _(max) and T _(max) were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed AUC, C_(max), and untransformed T_(max). The results showed that the differences between two formulations based on the BUP-4 were 0.17%, 7.98% and 4.55% for AUC,, C_(max), and respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically trans-formed data were within the acceptance range of log(0.8) to log(1.25) (e.g., log(0.88)-log(l .12) and log(0.90)-log(l.15) for AUC, and _(max), respectively). Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Kuhnil Propiverine Hydrochloride tablet was bioequivalent to BUP-4 tablet.

조기위함에서 침윤, 유형 및 분화도에 따른 p53, bcl-2의 발현

권오선,조현득,오미혜,김의한,양승하 순천향대학교 의학연구소 2006 Journal of Soonchunhyang Medical Science Vol.12 No.2

..

Enamel matrix derivative(EMDOGAIN^(R))을 이용한 상악 소구치의 자가이식 치험례

오유향,김효식,정현구,조태식,위유민,이창섭 조선대학교 구강생물학연구소 2002 Oral Biology Research (Oral Biol Res) Vol.26 No.2

The success of tooth transplantation or replantation depends on the viability of periodontal ligament in the transplanted tooth. Mechanical injury to periodontal tissues frequently results in dental root resorption and ankylosis, which leads to the failure of transplantation or replantation. Enamel matrix derivative (EMD) has been recently used to induce periodontal regeneration. In this report, we show a clinical case of EMD application in the transplantation of an inversely impacted and immature tooth. An impacted second premolar was found in the right maxilla of a 14 year-old girl. The tooth was inversely impacted and the root formation was incomplete. When transplantation was carried out. EMD was applied to the periodontal tissues of the extracted premolar. The tooth was fixed at the correct position and the clinical condition was followed for evaluation for 3 months. Radiographs after 3 months exhibited new bone formation surrounding the transplanted tooth. There were no signs of root resorption or ankylosis, and reconstruction of the bone defect area at the maxilla was also found. Short-term results from this case indicated that EMD application was effective in the transplantation of an inversely impacted and immature tooth. In adddition, EMD might contribute to obtain good healing without ankylosis. Further follow-up observations are necessary to evaluate the regenerative effects of EMD.

시클러 캡슐(세파클러 250㎎)에 대한 경보세파클러 캡슐의 생물학적동등성

조혜영,강현아,김세미,박찬호,오인준,임동구,문재동,이용복 한국약제학회 2005 Journal of Pharmaceutical Investigation Vol.35 No.1

The purpose of the present study was to evaluate the bioequivalence of two cefaclor capsules, Ceclor (Lilly Korea Co., Ltd.) and Kyongbocefaclor (Kyongbo Pharm. Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The release of cefaclor from the two cefaclor formulations in vitro was tested using KP VIII Apparatus II method with various dissolution media (pH 1.2. 4.0. 6.8 buffer solution and water). Twenty four healthy male subjects. 22.96±1.52 years in age and 67.03±7.90 kg in body weight, were divided into two groups and a randomized 2x2 cross-over study was employed. After one capsule containing 250 mg of cefaclor was orally administered, blood was taken at pre-determined time intervals and the concentrations of cefaclor in serum were determined using HPLC method with UV detector. The dissolution profiles of two formulations were similar at all dissolution media. In addition. the pharmacokinetic parameters such as AUC_(t), C_(max) and T _(max) were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed AUC_(t). C_(max) and untransformed Tmaa. The results showed that the differences between two formulations based on the reference drug, Ceclor. were -1.90%, 2.68% and -7.60% for AUCt, C_(max) and T_(max), respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log 0.8 to log 1.25 (e.g., log 0.91-log 1.06 and log 0.92-log 1.18 for AU', and C_(max), respectively). Thus. the criteria of the KFDA bioequivalence guideline were satisfied, indicating Kyongbocefaclor capsule was bioequivalent to Ceclor capsule.